HCV genotypes in Morocco

Benani, Abdelouahab; El-Turk, Joumana; Benjelloun, Soumaya; Sekkat, Souad; Nadifi, Sellama; Hda, Nezha; Benslimane, A.

doi:10.1002/(sici)1096-9071(199708)52:4<396::aid-jmv9>3.0.co;2-x

Cited by 23 publications

(11 citation statements)

References 18 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The results are scarce and heterogeneous, probably reflecting regional differences in the distribution of HCV genotypes. In the majority of the regions studied, subtype 1b was the most prevalent among patients on hemodialysis [Bouchardeau et al, 1995;Colleoni et al, 1996;Lee et al, 1996;Benani et al, 1997;Bogomolski-Yahalom et al, 1997;Burjel et al, 1998;Chan et al, 1998;Schneeberger et al, 1998]. In the United States, a survey among kidney transplant candidates identified subtype 1a as the most prevalent [Natov et al, 1999].…”

Section: Discussionmentioning

confidence: 98%

Unexpected distribution of hepatitis C virus genotypes in patients on hemodialysis and kidney transplant recipients

Perez

Ferraz

Figueiredo

et al. 2003

Journal of Medical Virology

View full text Add to dashboard Cite

The distribution of hepatitis C virus (HCV) genotypes in patients on hemodialysis and in kidney transplant recipients was compared with that observed in a control group composed of HCV-infected individuals from the general population. A total of 340 patients were included in the study: 46 with end-stage renal disease on regular hemodialysis treatment, 22 kidney transplant recipients and 272 controls matched for sex and age at a 4:1 ratio (controls to patient). HCV genotype was determined by sequencing of the 5' untranslated region of the HCV genome. No difference was observed in the distribution of HCV genotypes in hemodialysis patients and renal transplant patients (P = 0.47). However, when each of these groups was compared with the control group, a significant difference was detected in the genotype distribution (P < 0.001). In hemodialysis and renal transplant patients the most prevalent subtype was 1a, followed by 1b, 3, and other less prevalent genotypes (2, 4, and 5), whereas in the control group the most prevalent subtype was 1b, followed by 3, 1a, and others. That observation may reflect differences in the epidemiology of HCV infection, viral characteristics and host factors in renal patients in comparison to the control group.

show abstract

Section: Discussionmentioning

confidence: 98%

Unexpected distribution of hepatitis C virus genotypes in patients on hemodialysis and kidney transplant recipients

Perez

Ferraz

Figueiredo

et al. 2003

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…In Germany, 77.6% of patients receiving HD are genotype 1 [4]. Although genotype 1a is prevalent in the general population, genotype 1b is more prevalent in patients undergoing HD in the Netherlands [11], Mexico [44], Morocco [45], and France [46]; genotype 2a in Italy [47]; genotypes 1a and 1b in Israel [48] and Indonesia [21]; and genotype 1 in Canada [49]. We may thus conclude that genotypes 1 and 2 are more prevalent in North America and Europe (60%-70%), genotype 3 is more prevalent in the Far East, Asia, and Australia, genotype 4 is more prevalent in Africa and the Middle East, genotype 5 is more prevalent in South Africa, and genotype 6 is more prevalent in Hong Kong.…”

Section: Discussionmentioning

confidence: 99%

Distribution of HCV Genotypes in Patients with End-Stage Renal Disease According to Type of Dialysis Treatment

et al. 2006

View full text Add to dashboard Cite

The objective of this study was to investigate the effects of types of dialysis treatments on hepatitis C virus infection and the epidemiologic properties of hepatitis C virus (HCV) infection at three Baskent University hospitals, in Ankara, Adana, and Izmir, Turkey, in 655, 326, and 118 patients with end-stage renal disease, respectively. One hundred thirty patients with HCV viremia among 271 patients with end-stage renal disease seropositive for HCV were included in this cross-sectional study. HCV RNA-positive patients were classified according to the renal replacement therapies (hemodialysis or continuous ambulatory peritoneal dialysis), and viral load, transaminase levels, and distribution of genotypes were compared between these subgroups. In the continuous ambulatory peritoneal dialysis group, 26 of 165 patients (16%) were serum anti-HCV positive, and 11 of 26 patients (42%) were serum HCV RNA positive. Twenty-six percent of the patients undergoing hemodialysis were anti-HCV positive, and 49% were HCV RNA positive. The prevalence of genotype 1b was 68% and 73% for patients in the continuous ambulatory peritoneal dialysis and hemodialysis groups, respectively. No significant differences were found between the genotype 1b and the non-1b groups or between different dialysis types with regard to age and sex and serum aspartate transaminase, alanine aminotransferase, and HCV RNA levels. We conclude that HCV seropositivity may differ between different types of dialysis treatments, although viral load and genotypes may be similar in persons with end-stage renal disease and those without.

show abstract

“…In Morocco, early reports about HCV genotypes indicated that the most common was 1b (47.6%) followed by 2a/2c (37.1%) and the less frequent 1a (2.8%). Furthermore, the subtype 1b was most prevalent among older patients, whereas subtype 2a/2c was mainly found among younger ones [Benani et al, ]. Recently, another study conducted in 185 patients chronically infected with HCV, revealed that the main viral subsets belong to subtypes 1b (75.2%) followed by 2i (19.1%), 2k (2.8%) whereas genotype 4 is very rare (0.7%) (Fig.…”

Section: Hcv Genotypes/subtypes In the Maghreb Regionmentioning

confidence: 99%

Hepatitis C virus infection in the Maghreb region

Ezzikouri

Pineau

Benjelloun

2013

Journal of Medical Virology

Self Cite

View full text Add to dashboard Cite

Hepatitis C is a global health problem with a worldwide prevalence of about 3% (around 170 million people). Hepatitis C virus (HCV) is major concern in the Maghreb countries, Algeria, Libya, Mauritania, Morocco, and Tunisia, but no detailed description of its epidemiology in the region is available. In the present review, a systematic search was undertaken covering HCV data available in peer-reviewed databases as well as institutional reports and regional conference meeting abstracts from the Maghreb countries. Reports written in English and French were included in this analysis. Estimates of national and regional prevalence of HCV infection (based on anti-HCV antibody) and of the size of patient populations were performed. In addition, the molecular features of the circulating viral strains in the region are discussed. A substantial proportion, 1.2-1.9% of the Maghreb inhabitants, have anti-HCV antibodies. Genotype 1b predominates among viral strains in all countries except in Libya, where genotype 4 is dominant as in neighboring Egypt. This epidemiological situation is of significant concern, and requires urgent, broad, and active intervention for the prevention and control of HCV. More specifically, the application of state-of-the-art hygiene procedures and rigorous controls in medical disciplines such as hemodialysis, transfusion, endoscopic procedures, and dentistry is necessary to reduce significantly the number of new infections in the region.

show abstract

HCV genotypes in Morocco

Cited by 23 publications

References 18 publications

Unexpected distribution of hepatitis C virus genotypes in patients on hemodialysis and kidney transplant recipients

Unexpected distribution of hepatitis C virus genotypes in patients on hemodialysis and kidney transplant recipients

Distribution of HCV Genotypes in Patients with End-Stage Renal Disease According to Type of Dialysis Treatment

Hepatitis C virus infection in the Maghreb region

Contact Info

Product

Resources

About